Glimepiride 3 mg + Metformin 500 mg PCD Pharma Franchise

Brand Name

GLISOT-M3 Tablet (Bilayered)

Composition

Glimepiride 3mg & Metformin 500mg (Prolonged Release)

Therapeutic Use

ANTIDIABETICS

Size

10 x 15

Verified Exporter

Verified Seller

Trusted Pharma

Description

GLISOT-M3 Tablet (Bilayered) contains Glimepiride 3 mg and Metformin 500 mg prolonged release, a combination of two oral antidiabetic medicines used to help manage blood glucose levels in adults with type 2 diabetes mellitus when prescribed by a qualified healthcare professional. Glimepiride belongs to the sulfonylurea class and stimulates insulin release, while prolonged-release Metformin belongs to the biguanide class and primarily reduces glucose production in the liver and improves insulin sensitivity.

This combination may be considered when a healthcare professional determines that both active ingredients are appropriate for an individual’s diabetes management plan. Treatment should be supported by appropriate dietary measures, physical activity and regular blood glucose monitoring. The exact prolonged-release formulation and administration instructions must be confirmed against the approved product label.

CardianCare focuses on cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business partners. Businesses searching for a Glimepiride 3 mg + Metformin 500 mg prolonged-release Tablets manufacturer India can enquire about current product availability, approved specifications and applicable quality documentation.

For procurement teams evaluating a Glimepiride 3 mg + Metformin 500 mg prolonged-release Tablets manufacturer and supplier India, important considerations include composition accuracy, release characteristics, product authorization, packaging, batch traceability, shelf life and applicable supply terms.

2. Key Ingredient

Composition:

Glimepiride 3 mg + Metformin 500 mg

Glimepiride 3 mg: Glimepiride is a sulfonylurea antidiabetic medicine that stimulates pancreatic beta cells to release insulin. The released insulin helps lower elevated blood glucose levels. Because Glimepiride stimulates insulin secretion, it can cause hypoglycaemia, particularly when meals are skipped or other glucose-lowering medicines are used.

Metformin 500 mg prolonged release: Metformin is a biguanide that primarily reduces glucose production in the liver and improves the body’s response to insulin. The prolonged-release formulation is designed to release the medicine over an extended period; the precise release characteristics and administration instructions should be verified using the approved product information.

Businesses researching a Glimepiride 3 mg + Metformin 500 mg pharmaceutical company India should assess the composition, approved labelling, release formulation, manufacturing source and applicable quality documentation.

Companies seeking a Glimepiride 3 mg + Metformin 500 mg medicine manufacturer India should verify the manufacturing source, product authorization, batch documentation and relevant regulatory requirements before entering into a commercial supply arrangement.

3. Key Benefits

Complementary glucose-lowering action: Combines insulin secretion stimulation with reduced hepatic glucose production and improved insulin sensitivity.

Type 2 diabetes management: May help improve glycaemic control in eligible adults when prescribed appropriately.

Two established antidiabetic classes: Combines a sulfonylurea with a biguanide, each working through a different mechanism.

Oral treatment option: Provides an oral combination for patients for whom both ingredients are clinically appropriate.

Individualized treatment planning: Allows the prescriber to consider two glucose-lowering mechanisms within an overall diabetes management plan.

Lifestyle management support: Can be used alongside clinician-recommended dietary measures, physical activity and regular blood glucose monitoring.

The clinical response varies according to the patient’s health status, kidney function, diet, adherence and other medicines. Glimepiride increases the risk of hypoglycaemia, while Metformin requires attention to kidney function and the rare risk of lactic acidosis. Treatment suitability should be assessed by a qualified healthcare professional.

Pharmaceutical buyers searching for a Glimepiride 3 mg + Metformin 500 mg supplier India should verify current product availability, composition, approved release formulation, batch information and shelf life.

A Glimepiride 3 mg + Metformin 500 mg Tablet wholesaler and distributor India enquiry may include product availability, distribution eligibility, order requirements, delivery arrangements and applicable commercial terms.

Businesses looking for a Glimepiride 3 mg + Metformin 500 mg bulk supplier India should request formal product and supply information, including packaging specifications, storage requirements, expiry details and batch traceability.

A Glimepiride 3 mg + Metformin 500 mg pharmaceutical distributor India should verify product authorization, maintain appropriate storage and distribution practices, and communicate using approved product information.

4. How Does It Work?

The two active ingredients support blood glucose management through complementary mechanisms.

Glimepiride: Stimulates insulin secretion from pancreatic beta cells. It acts on sulfonylurea receptors associated with ATP-sensitive potassium channels, triggering cellular changes that promote insulin release. The released insulin helps body tissues take up glucose from the bloodstream.

Metformin prolonged release: Primarily reduces glucose production in the liver and improves insulin sensitivity in body tissues. This helps the body use insulin more effectively and contributes to blood glucose control.

Together, these mechanisms can support glycaemic management in appropriately selected adults with type 2 diabetes. However, Glimepiride can cause low blood glucose, and Metformin requires particular attention to kidney function and the risk of lactic acidosis in susceptible patients.

5. Directions for Use

Dosage: Take only as prescribed by a doctor. The appropriate regimen depends on blood glucose control, kidney function, other medicines and individual clinical factors.

Administration: Follow the approved product label and the prescriber’s instructions for the bilayered prolonged-release formulation.

With food: Metformin prolonged-release formulations are commonly taken with food. Confirm the correct timing for this specific product with the prescriber or approved leaflet.

Swallowing: Do not crush, chew or split the Tablet unless the approved product information specifically permits it, as this may affect its release characteristics.

Regular timing: Follow the prescribed schedule consistently. Do not change the dose independently.

Blood glucose monitoring: Monitor blood glucose as recommended by the treating clinician.

Missed dose: Follow the approved patient information or ask a doctor or pharmacist. Do not take a double dose to compensate for a missed dose.

Meals and hypoglycaemia: Avoid skipping meals and discuss meal planning with the healthcare professional because Glimepiride can cause low blood glucose.

Kidney function: Kidney function should be assessed before and during Metformin treatment as clinically indicated.

Lifestyle management: Continue recommended dietary measures, physical activity and medical follow-up.

The 3 mg Glimepiride strength is not suitable for every patient. The prescriber should determine the appropriate regimen based on the patient’s clinical needs and the approved product information.

6. Possible Side Effects

Possible side effects associated with Glimepiride and Metformin include:

Hypoglycaemia: Low blood glucose, potentially causing sweating, shakiness, dizziness, hunger, headache, confusion or weakness.

Gastrointestinal symptoms: Nausea, diarrhoea, abdominal discomfort, bloating or reduced appetite, particularly with Metformin.

Taste changes: Some patients may experience a metallic taste.

Vitamin B12 reduction: Long-term Metformin use may lower vitamin B12 levels.

Weight changes: Weight effects can vary between individuals and with the overall treatment plan.

Important warning signs:

Severe hypoglycaemia: Confusion, seizures or loss of consciousness require emergency medical attention.

Possible lactic acidosis: Unusual severe weakness, muscle pain, breathing difficulty, unusual sleepiness or abdominal symptoms accompanied by feeling very unwell require urgent assessment, particularly in patients with kidney impairment, severe dehydration or serious illness.

Allergic reaction: Facial or throat swelling or difficulty breathing requires emergency care.

This list is not exhaustive. Report persistent or concerning symptoms to a healthcare professional.

7. Safety Information

Medical supervision: Use only under the guidance of a qualified healthcare professional.

Type 1 diabetes: This combination is not intended to treat type 1 diabetes or diabetic ketoacidosis.

Hypoglycaemia: The risk is associated particularly with Glimepiride and can increase when meals are skipped, during fasting, with alcohol or with certain interacting medicines.

Kidney function: Metformin is unsuitable in severe renal impairment. Kidney function should be assessed before treatment and monitored as recommended by the clinician.

Liver health: Inform the prescriber about liver disease, as it may affect treatment suitability and the risk of lactic acidosis.

Dehydration and acute illness: Severe dehydration, serious infection, reduced oxygen supply or other acute illness may increase risks associated with Metformin. Seek medical advice promptly.

Surgery and medical procedures: Inform the healthcare team about Metformin use before surgery or procedures involving iodinated contrast. Temporary interruption may be needed in some circumstances under medical guidance.

Pregnancy: Consult a doctor before use during pregnancy or when planning pregnancy. The clinician should reassess the most appropriate diabetes treatment.

Breastfeeding: Seek medical advice before use while breastfeeding.

Drug interactions: Inform the doctor about all prescription medicines, over-the-counter products and supplements, including insulin and other glucose-lowering medicines.

Alcohol: Avoid excessive alcohol and discuss alcohol use with the prescriber because it can increase treatment-related risks.

Storage: Store in the original packaging according to the approved product label, protected from excessive heat and moisture and out of children’s reach.

This information is educational and does not replace approved prescribing information or individualized medical advice.

8. B2B Pharmaceutical Business Enquiries

CardianCare focuses on cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business partners. Pharmaceutical distributors, wholesalers, procurement teams and other eligible business partners can contact the company to enquire about current product availability and applicable commercial arrangements.

Businesses researching a Glimepiride 3 mg + Metformin 500 mg prolonged-release PCD pharma franchise India opportunity should confirm whether the product is included in a current programme. Product eligibility, territory availability, partner requirements and commercial terms require direct verification.

For a Glimepiride 3 mg + Metformin 500 mg prolonged-release Tablets PCD pharma franchise enquiry, prospective partners may request information about eligible products, order requirements, distribution conditions and approved promotional materials.

Companies exploring a Glimepiride 3 mg + Metformin 500 mg prolonged-release Tablet PCD franchise should verify programme availability and applicable terms before making investment or promotional commitments.

Businesses researching Glimepiride 3 mg + Metformin 500 mg prolonged-release third party manufacturing India should first confirm whether the proposed company offers such services. If applicable, due diligence should include manufacturing permissions, product approvals, applicable GMP compliance, formulation specifications and quality agreements.

A Glimepiride 3 mg + Metformin 500 mg prolonged-release Tablet third party manufacturer India enquiry should cover manufacturing authorization, release-formulation requirements, quality control procedures, packaging specifications, batch documentation and contractual responsibilities.

Companies investigating Glimepiride 3 mg + Metformin 500 mg prolonged-release contract manufacturing India should confirm service availability and discuss technical documentation, formulation specifications, regulatory responsibilities, quality agreements, minimum batch quantities and commercial feasibility with the proposed partner.

Visit & contact CardianCare regarding current product availability, pharmaceutical business enquiries and applicable arrangements. PCD franchise, distribution and manufacturing services should be verified directly with the company before being represented as available.

9. For More Information

For more information about GLISOT-M3 Tablet (Bilayered) – Glimepiride 3 mg + Metformin 500 mg prolonged release, click here

Frequently Asked Questions

This combination may be prescribed to improve blood glucose control in adults with type 2 diabetes when both active ingredients are considered appropriate by a healthcare professional. It is used alongside dietary measures, physical activity and blood glucose monitoring.

The stated composition is Glimepiride 3 mg and Metformin 500 mg prolonged release. The release designation and administration instructions should be checked against the approved product label.

Glimepiride stimulates insulin release, while Metformin reduces glucose production in the liver and improves insulin sensitivity. Their complementary actions can support blood glucose management.

It provides two different glucose-lowering mechanisms in an oral combination for appropriately selected adults with type 2 diabetes. Clinical suitability depends on individual needs and the prescriber's assessment.

Take it exactly as prescribed and follow the approved product instructions. Metformin prolonged-release formulations are commonly taken with food. Do not crush, chew or split the Tablet unless the product information explicitly permits it.

Possible effects include hypoglycaemia, nausea, diarrhoea, abdominal discomfort, bloating and taste changes. Long-term Metformin treatment may lower vitamin B12 levels.

Important considerations include low blood glucose, kidney function, liver disease, dehydration, serious illness, alcohol use, drug interactions, pregnancy and breastfeeding. Seek professional advice before starting or changing treatment.

Glimepiride stimulates insulin release from the pancreas. Metformin primarily reduces glucose production in the liver and improves insulin sensitivity. They belong to different antidiabetic classes and have different safety considerations.

Store the medicine in its original packaging according to the approved product label. Protect it from excessive heat and moisture and keep it out of children's reach.

Eligible pharmaceutical businesses can visit https://CardianCare.com/ to enquire about product availability and applicable arrangements. Distribution, PCD franchise and manufacturing services must be confirmed directly with the company."

Reviews

There are no reviews yet.

Be the first to review “Glimepiride 3 mg + Metformin 500 mg PCD Pharma Franchise”

Your email address will not be published. Required fields are marked *

Enquiry Now
close slider

    Drop us a Line